ReNeuron Group plc Director/PDMR Shareholding (1140Y)
02 Septembre 2022 - 12:01PM
UK Regulatory
TIDMRENE
RNS Number : 1140Y
ReNeuron Group plc
02 September 2022
ReNeuron Group plc
("ReNeuron" or "the Group")
Share Purchase by a Director
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell
derived exosome technologies , announces that Iain Ross, Chairman
of the Company, has today purchased 100,000 of the Company's
ordinary shares of 1p each ("Ordinary Shares").
Name Title Number of Resulting Percentage
Ordinary beneficial of Company's
Shares purchased interest in Total Voting
the Company's Rights
Ordinary Shares
Iain Ross Chairman 100,000 100,000 0.175%
---------- ------------------ ----------------- --------------
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
Catherine Isted, Chief Executive Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3110 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus +44 (0)7980 541 893
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived
exosome technologies, harnessing its unique stem cell technologies
to develop 'off the shelf' treatments for diseases with significant
unmet needs.
ReNeuron's stem cell derived proprietary exosome technology
platform offers a delivery mechanism for a variety of payloads such
as siRNA, mRNA, proteins, small molecules and genes. The Group has
a growing number of partner collaborations with Global Pharma,
Biotech and academic partners in this fast-expanding area of
scientific and commercial interest. ReNeuron also has the ability,
through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and
has the potential to produce exosomes with tissue specific
targeting ability.
The Group has out-licenced its CTX Programme for stroke
disability and hRPC programme in retinitis pigmentosa to Fosun in
China and is looking to out-license both of these programmes in
other territories.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to ordinary shares purchased by
Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Iain Gladstone Ross
--------------------------- --------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chairman and Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- --------------------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
--------------------------- --------------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
--------------------------- --------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
25.85p 10,000
26.00p 30,000
27.70p 60,000
--------------------------- --------------------------------------------
d) Aggregated information 100,000 ordinary shares at an average price
of 27.005p at a total value of GBP27,005
--------------------------- --------------------------------------------
e) Date of the transaction 02 September 2022
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange AIM Market
--------------------------- --------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFIIAIIFIIF
(END) Dow Jones Newswires
September 02, 2022 06:01 ET (10:01 GMT)
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
